Clearly a few commentators on here need to understand lags in cash accounting particularly. The treatments were only available for purchase on 28 March.
What were you really expecting to see for a cash flow report ending 31 March? A report with only 4 days of cash flows where Ryoncil was available to purchase.
Whilst some cash flows from the early treatments will be evident in the July 4C, the August accrual earnings report will be far more illustrative of early revenues. Some people have kindly demonstrated how to work out those likely figures for you above in advance.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-153
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.015(0.95%) |
Mkt cap ! $2.028B | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.63 | $1.58 | $2.801M | 1.751M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 53 | 61856 | $1.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 19217 | 31 |
View Market Depth
| Last trade - 12.57pm 25/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |